During Thursday’s Current trade, Shares of Costco Wholesale Corporation (NASDAQ:COST), lost -0.77% to $144.05.
Costco Wholesale Corporation ( COST) declared that its Board of Directors declared a quarterly cash dividend on Costco common stock of $.40 per share. The quarterly dividend is payable August 28, 2015, to shareholders of record at the close of business on August 14, 2015.
Costco presently operates 679 warehouses, counting 479 in the United States and Puerto Rico, 89 in Canada, 36 in Mexico, 26 in the United Kingdom, 20 in Japan, 11 in Korea, 10 in Taiwan, seven in Australia and one in Spain. The Company plans to open up to an additional seven new warehouses proceeding to the end of its fiscal year on August 30, 2015. Costco also operates electronic commerce web sites in the U.S., Canada, the United Kingdom and Mexico.
Costco Wholesale Corporation, together with its auxiliaries, operates membership warehouses. The company offers branded and private-label products in a range of merchandise categories. It provides dry and institutionally packaged foods; snack foods, candy, tobacco, alcoholic and nonalcoholic beverages, and cleaning and institutional supplies; appliances, electronics, health and beauty aids, hardware, garden and patio, and office supplies; meat, bakery, deli, and produce; and apparel, small appliances, and home furnishings.
Shares of Kite Pharma Inc (NASDAQ:KITE), declined -2.07% to $54.85, during its current trading session.
Kite Pharma, Inc. (KITE) and bluebird bio, Inc. (BLUE) declared that they have reached a partnershipagreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, counting HPV-16 E6 TCR, presently in a Phase I study, and HPV-16 E7 TCR. The partnership brings together the powerful technologies and capabilities of these two leading immunotherapy companies.
Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.
Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, counting research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers.
Fluor Corporation (NEW) (NYSE:FLR), during its Thursday’s current trading session decreased -1.87% to $46.66.
Fluor Corporation (NEW) (FLR) declared that the U.S.-China Business Council (USCBC) has elected Fluor’s Chief Operating Officer, Peter Oosterveer, to its board. As a USCBC board member, Oosterveer will work to advance the commercial relationship between the two countries to support trade and investment opportunities.
Fluor Corporation, through its auxiliaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project administration services worldwide. The company operates in five segments: Oil & Gas, Industrial & Infrastructure, Government, Global Services, and Power. The Oil & Gas segment offers a range of design, engineering, procurement, construction, and project administration services to upstream oil and gas production, liquefied natural gas, downstream refining, offshore production, pipeline, chemicals, and petrochemicals industries. It also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies.
Finally, Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH), decreased -2.58%, to $58.18.
Norwegian Cruise Line Holdings Ltd. (NCLH) together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings”, “Norwegian” or the “Company”, stated financial results for the quarter ended June 30, 2015 and offered guidance for the third quarter and full year 2015.
Second Quarter 2015 Highlights
- Improvement in Adjusted EPS of 29.3% to $0.75 on Adjusted Net Income of $171.6 million.
- Enhance in Adjusted Net Yield on a Combined Company basis of 1.5%, or 3.2% on a Constant Currency basis, driven by pricing improvement in the quarter. Enhance of 18.2% on an as stated basis.
- Continued synergy identification efforts from the integration of Norwegian and Prestige lead to synergies of $75 million in 2015 and $125 million in 2016 preceding to reinvestment.
Norwegian Cruise Line Holdings Ltd., a cruise line operator, through its auxiliaries, provides cruise experiences for travelers with various itineraries. It offers cruises ranging from 1 day to 180 days. The company’s distribution channel comprises independent travel agents, wholesalers, and tour operators. It operates 21 ships under the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands with about 40,000 lower berths visiting about 430 destinations worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
